Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression

Clinical-stage psychedelics biotech Cybin Inc. CYBN and psychedelic therapy education organization Fluence have signed an agreement to support the streamlining and scaling of the former’s EMBARK facilitator training program in light of an upcoming global Phase 3 trial of deuterated psilocybin analog CYB003 for major depressive disorder (MDD) treatment.

Cybin’s streamlined model of psychedelic facilitation training, titled EMBARK for Clinical Trials (or EMBARKCT), is designed for individuals with existing experience, knowledge and skills in psychedelic facilitation.

Fluence will support Cybin in selecting and training facilitators for its planned Phase 3 trial, produce additional video content, and offer both real-time and self-paced training to enhance and verify the facilitators’ competencies.

Cybin CEO Doug Drysdale says the new partnership is another important part of the company’s “readiness planning” to advance its CYB003 program toward pivotal studies.

See Also: Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

"Leveraging Fluence’s expertise in clinical training and education, we will be able to deliver high-quality, scalable treatment facilitation training capable of supporting a larger Phase 3 trial," Drysdale stated.

For its part, the education organization has been an active player in the training scene: Besides recently partnering with a Brazilian nonprofit research institute, as many as 25 graduates from Fluence’s first psilocybin-assisted therapy program cohort are on track to request their licenses to lawfully provide such therapy in Oregon.

Fluence co-founder Dr. Ingmar Gorman said Cybin is “making significant strides in psychedelic drug development” and that the collaboration “exemplifies how forward-looking drug developers are addressing the critical need for facilitator training.” 

See Also: Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures

The aim of the collaborative effort, Gorman reaffirmed, is to co-create a scalable program that will support a multi-site, global Phase 3 trial of CYB003 “that ultimately contributes to the development of a successful ecosystem in this emerging and transformative field."

Photo: Benzinga edit with photo by Krakenimages.com and Cannabis_Pic on Shutterstock.